Efficacy and safety of nivolumab plus ipilimumab versus nivolumab alone in patients with advanced melanoma: a systematic review and meta-analysis
CONCLUSIONS: Given diversity and potential biases, oncologists should base immunotherapy decisions on professional expertise and patient characteristics.REGISTRATION: PROSPERO registration number: CRD42023453484.PMID:38532600 | DOI:10.1080/14737140.2024.2336106
Source: Expert Review of Anticancer Therapy - Category: Cancer & Oncology Authors: Shuting Cui Xiaozhe Sun Junxi Gao Source Type: research
More News: Cancer & Oncology | Databases & Libraries | Immunotherapy | Melanoma | Science | Skin Cancer | Study | Yervoy